


Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:

R¹ represents -C₁₋₆ alkyl substituted by one or more (e.g. 1, 2 or 3) halogen or cyano groups, -C₀₋₄ alkyl-C₃₋₈cycloalkyl, -C₂₋₄ alkoxy-C₁₋₄ alkyl, -C₁₋₄ alkyl-aryl, -C₁₋₄ alkyl-heteroaryl or -C₀₋₄ alkyl-heterocyclyl;

wherein said cycloalkyl, aryl, heteroaryl or heterocyclyl groups of R¹ may be optionally substituted by one or more (e.g. 1, 2 or 3) halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl groups;

R² represents hydrogen or C₁₋₆ alkyl;

m represents an integer from 1 to 4, such that when m is an integer greater than 1, two R² groups may instead be linked to form a CH₂, (CH₂)₂ or (CH₂)₃ group;

R³, R⁴ and R⁵ independently represent hydrogen, halogen, cyano, -CF₃, -CF₃O, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkanoyl or a group -CONR⁶R⁷;

R⁶ and R⁷ independently represent hydrogen or C₁₋₆ alkyl or R⁶ and R⁷ together with the nitrogen to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

n represents an integer from 1 to 3;

p represents 1 or 2;

A represents an -aryl, -heteroaryl, -aryl-aryl, -aryl-heteroaryl, -heteroaryl-aryl or -heteroaryl-heteroaryl group;

wherein said aryl and heteroaryl groups of A may be optionally substituted by one or more (e.g. 1, 2 or 3) substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C₁₋₆ alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C₁₋₆ alkoxy, arylC₁₋₆ alkoxy, C₁₋₆ alkylthio, C₁₋₆ alkoxyC₁₋₆ alkyl, C₃₋₇ cycloalkylC₁₋₆ alkoxy, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyloxy, C₁₋₆ alkylsulfonylC₁₋₆ alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC₁₋₆ alkyl, C₁₋₆ alkylsulfonamido, C₁₋₆ alkylamido, C₁₋₆ alkylsulfonamidoC₁₋₆ alkyl, C₁₋₆ alkylamidoC₁₋₆ alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC₁₋₆ alkyl, arylcarboxamidoC₁₋₆

alkyl, aroyl, aroylC₁₋₆ alkyl, arylC₁₋₆ alkanoyl, or a group CONR⁸R⁹ or SO₂NR⁸R⁹, wherein R⁸ and R⁹ independently represent hydrogen or C₁₋₆ alkyl or R⁸ and R⁹ together with the nitrogen atom to which they are attached may form a nitrogen containing heterocyclyl or heteroaryl group;

5 or solvates thereof.

2. A compound of formula (I) as defined in claim 1 which is:

8-(4-(4-Fluorobenzyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;

8-(4-Cyclopropylmethyl-piperazin-1-yl)-3-phenylsulfonylquinoline;

10 8-(4-(Cyclohexyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;

8-(4-Cyclopentyl-piperazin-1-yl)-3-phenylsulfonylquinoline;

8-(4-Cyclobutyl-piperazin-1-yl)-3-phenylsulfonylquinoline;

8-(4-Cyclopropyl-piperazin-1-yl)-3-phenylsulfonylquinoline;

8-(4-(2-methoxyethyl)-piperazin-1-yl)-3-phenylsulfonylquinoline;

15 8-(4-(2,2,2-Trifluoroethyl)-piperazin-1-yl)-3-(4-fluoro)-phenylsulfonylquinoline;

or a pharmaceutically acceptable salt thereof.

3. A pharmaceutical composition which comprises a compound as defined in claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

20

4. A compound as defined in claim 1 or claim 2 for use in therapy.

5. A compound as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

25

6. The use of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment or prophylaxis of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

30

7. A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1 or claim 2 for use in the treatment of depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke.

35

8. A method of treating depression, anxiety, Alzheimer's disease, age related cognitive decline, ADHD, obesity, mild cognitive impairment, schizophrenia, cognitive deficits in schizophrenia and stroke which comprises administering a safe and therapeutically effective amount to a patient in need thereof of a compound of formula (I) as defined in claim 1 or claim 2 or a pharmaceutically acceptable salt thereof.

40